What Can We Learn from Parents About Enhancing Participation in Pharmacovigilance?

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 Aug 22

PMID 22905902

Citations 12

Authors

Janine Arnott

Hannah Hesselgreaves

Anthony J Nunn

Matthew Peak

Munir Pirmohamed

Rosalind L Smyth

Mark A Turner

Bridget Young

Affiliations

Soon will be listed here.

Abstract

Aims: To investigate parents' views and experiences of direct reporting of a suspected ADR in their child.

Methods: We audio-recorded semi-structured qualitative interviews with parents of children with suspected ADRs. Our sample included parents with (n = 17) and without (n = 27) previous experience of submitting a Yellow Card.

Results: Parents in both groups described poor awareness of the Yellow Card Scheme. Parents who had participated in the Yellow Card Scheme were generally happy to report their child's ADR via the Scheme and valued the opportunity to report concerns independently of health practitioners. They expressed motivations for reporting that have not previously been described linked to the parental role, including how registering a concern about a medicine helped to resolve uncomfortable feelings about their child's ADR. Parents who had not previously submitted a Yellow Card expressed uncertainty about the legitimacy of their involvement in reporting and doubts about the value of the information that they could provide.

Conclusion: Promoting wider participation in pharmacovigilance schemes will depend on raising public awareness. Additionally, our findings point to the need to empower lay people to submitting reports and to reassure them about the value of their reports.

Citing Articles

Factors Associated with the Public's Intention to Report Adverse Drug Reactions to Community Pharmacists in the Makkah Region of Saudi Arabia: An Application of the Theory of Planned Behavior.

Alsulami F Patient Prefer Adherence. 2024; 18:2495-2506.

PMID: 39678360 PMC: 11646385. DOI: 10.2147/PPA.S495487.

Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework.

Shafei L, Mekki L, Maklad E, Alhathal T, Ghanem R, Almalouf R Int J Clin Pharm. 2023; 45(4):801-813.

PMID: 37247158 PMC: 10366238. DOI: 10.1007/s11096-023-01591-z.

Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis.

Zondi S, Naidoo P BMC Health Serv Res. 2022; 22(1):1054.

PMID: 35982442 PMC: 9389709. DOI: 10.1186/s12913-022-08395-3.

Parental reporting of adverse drug reactions in South Africa: An online survey.

Pillay S, Mulubwa M, Viljoen M Afr J Prim Health Care Fam Med. 2021; 13(1):e1-e8.

PMID: 34636609 PMC: 8517735. DOI: 10.4102/phcfm.v13i1.2880.

Consumer opinions on adverse events associated with medicines and vaccines.

Aslani P, Hamrosi K, Tong V, Chen T, Cook J, Fois R Patient Prefer Adherence. 2018; 12:1383-1392.

PMID: 30104865 PMC: 6074778. DOI: 10.2147/PPA.S167396.

References

Anderson C, Gifford A, Avery A, Fortnum H, Murphy E, Krska J . Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme. Health Expect. 2011; 15(4):433-40. PMC: 5060635. DOI: 10.1111/j.1369-7625.2011.00686.x. View

Smith C, Bennett P, PEARCE H, Harrison P, Reynolds D, Aronson J . Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996; 42(4):423-9. PMC: 2042689. DOI: 10.1046/j.1365-2125.1996.04376.x. View

van Grootheest K, de Jong-van den Berg L . Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf. 2004; 3(4):363-8. DOI: 10.1517/14740338.3.4.363. View

Grinyer A . Young adults with cancer: parents' interactions with health care professionals. Eur J Cancer Care (Engl). 2004; 13(1):88-95. DOI: 10.1111/j.1365-2354.2004.00458.x. View

Ball L, Evans G, Bostrom A . Risky business: challenges in vaccine risk communication. Pediatrics. 1998; 101(3 Pt 1):453-8. DOI: 10.1542/peds.101.3.453. View

van Hunsel F, Harmark L, Pal S, Olsson S, van Grootheest K . Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2011; 35(1):45-60. DOI: 10.2165/11594320-000000000-00000. View

Casiday R, Cox A . Restoring confidence in vaccines by explaining vaccine safety monitoring: is a targeted approach needed?. Drug Saf. 2006; 29(12):1105-9. DOI: 10.2165/00002018-200629120-00002. View

Tobaiqy M, Stewart D, Helms P, Bond C, Lee A, McLay J . Views of parents and pharmacists following participation in a paediatric pharmacovigilance study. Pharm World Sci. 2010; 32(3):334-8. DOI: 10.1007/s11096-010-9374-0. View

Lorimer S, Cox A, Langford N . A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2011; 37(2):148-52. DOI: 10.1111/j.1365-2710.2011.01258.x. View

10.

Jong G, Stricker B, Choonar I, van den Anker J . Lack of effect of the European guidance on clinical investigation of medicines in children. Acta Paediatr. 2002; 91(11):1233-8. DOI: 10.1080/080352502320777487. View

11.

Vallano A, Cereza G, Pedros C, Agusti A, Danes I, Aguilera C . Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005; 60(6):653-8. PMC: 1884880. DOI: 10.1111/j.1365-2125.2005.02504.x. View

12.

Anderson C, Krska J, Murphy E, Avery A . The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011; 72(5):806-22. PMC: 3243015. DOI: 10.1111/j.1365-2125.2011.03990.x. View

13.

Avery A, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford P . Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011; 15(20):1-234, iii-iv. DOI: 10.3310/hta15200. View

14.

Tobaiqy M, Stewart D, Helms P, Williams J, Crum J, Steer C . Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK. Drug Saf. 2011; 34(3):211-9. DOI: 10.2165/11586050-000000000-00000. View

15.

Aagaard L, Nielsen L, Hansen E . Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009; 32(11):1067-74. DOI: 10.2165/11316680-000000000-00000. View

16.

Gust D, Darling N, Kennedy A, Schwartz B . Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics. 2008; 122(4):718-25. DOI: 10.1542/peds.2007-0538. View

17.

Blenkinsopp A, Wilkie P, Wang M, Routledge P . Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007; 63(2):148-56. PMC: 2000570. DOI: 10.1111/j.1365-2125.2006.02746.x. View

18.

Hazell L, Shakir S . Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006; 29(5):385-96. DOI: 10.2165/00002018-200629050-00003. View

19.

Mills E, Jadad A, Ross C, Wilson K . Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005; 58(11):1081-8. DOI: 10.1016/j.jclinepi.2005.09.002. View

20.

McLernon D, Bond C, Lee A, Watson M, Hannaford P, Fortnum H . Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf. 2011; 20(5):523-31. DOI: 10.1002/pds.2117. View